Search

TThe AMBAR (Alzheimer Management by Albumin Replacement) study by Grifols demonstrated that plasma exchange (PE) with albumin and immunoglobulin replacement could delay cognitive and functional decline in patients with mild-to-moderate Alzheimer’s disease (AD). Over a 14-month period, 347 patients received PE treatment, which involved six weeks of weekly PE sessions followed by 12 months of monthly low-volume PE. Key findings included:

• Cognitive and Functional Decline: Moderate AD patients showed significant improvement in Activities of Daily Living (52% less decline) and cognitive scores (66% less decline), with more stability in measures like the Clinical Dementia Rating and Global Impression of Change.
• Safety: While most PE procedures were uneventful, 10.6% had adverse events, with central venous access showing a higher rate of events than peripheral access.
• Treatment Effectiveness: The highest improvements were seen in patients with moderate AD, while mild AD patients showed less benefit.

The study supports PE with albumin and IVIG as a promising approach to slow AD progression, though further large-scale studies are recommended to confirm efficacy and safety.